If pharmacological inhibition of JAM-A, like JAM-A gene silencing, could attenuate FOXA1 levels, it will be exciting in future studies to test whether targeting JAM-A could contribute to overcoming endocrine resistance by acting as an upstream suppressor of FOXA1 expression in endocrine-resistant breast cancers. Here, F11R is linked to breast cancer.